José Miguel Pérez-Ruiz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
José Miguel Pérez-Ruiz has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Berta Miró
Bioinformatics and Statistical Unit, Vall d’Hebron Research Institute, 08035 Barcelona, Spain
1 shared publication - Edgar Iván Bravo-Castro
Department of Urology, Hospital Central Militar, Secretaría de la Defensa Nacional, Ciudad de México 11600, Mexico
1 shared publication - Enrique Trilla
Department of Urology, Vall d’Hebron University Hospital, Vall d’Hebron Research Institute (VHIR), 08025 Barcelona, Spain
1 shared publication - Guido Koren
Centro de Estudios Médicos e Investigación Clínica, Buenos Aires 1431, Argentina
1 shared publication - Joaquín Ignacio Gurovich
Department of Urology, Hospital Clínico Universidad de Chile, Independencia, Santiago 8380456, Chile
1 shared publication - Juan Camean
Department of Surgical Oncology, Instituto Alexander Fleming, Buenos Aires 1426, Argentina
1 shared publication
Latest Publications
- Open Access
External Validation and Clinical Impact of the Barcelona Predictive Models for Detecting Significant Prostate Cancer in Prostate Biopsies in an Ibero-American Population
Objectives: To externally validate the Barcelona Predictive Models (BCN-PM 1 and 2) for detecting csPCa in an Ibero-American population. BCN-PM 1 was designed to reduce magnetic resonance imaging (MRI) use, whereas BCN-PM 2 aims to decrease unnecessary prostate biopsies. Methods: This prospective, multicenter study included 661 men with suspected PCa recruited in 2025 across three Ibero-American centers. All participants underwent MRI followed by targeted biopsies of lesions with the Prostate Imaging–Reporting and Data System (PI-RADS) ≥ 3, along with systematic biopsy. When PI-RADS lesions were p < 0.001). Decision curve analysis demonstrated a net benefit for both models compared with strategies of biopsy in all or no men. BCN-PM 2 showed greater net benefit than BCN-PM 1. At 95% sensitivity, BCN-PM 1 reduced MRI requests by 10.6%, while BCN-PM 2 avoided 19.4% of unnecessary biopsies. The sequential use of BCN-PM 1 and 2 resulted in a 10.6% reduction in MRI exams and a 23.1% reduction in biopsies, at the cost of missing 8.4% of csPCa cases. The performance of the biopsy improved from 53.7% to 64.0% (p < 0.001). Conclusions: BCN-PM1 and BCN-PM 2 were successfully validated in an Ibero-American population.
Open AccessExternal Validation and Clinical Impact of the Barcelona Predictive Models for Detecting Significant Prostate Cancer in Prostate Biopsies in an Ibero-American Population
Objectives: To externally validate the Barcelona Predictive Models (BCN-PM 1 and 2) for detecting csPCa in an Ibero-American population. BCN-PM 1 was designed to reduce magnetic resonance imaging (MRI) use, whereas BCN-PM 2 aims to decrease unnecessary prostate biopsies. Methods: This prospective, multicenter study included 661 men with suspected PCa recruited in 2025 across three Ibero-American centers. All participants underwent MRI followed by targeted biopsies of lesions with the Prostate Imaging–Reporting and Data System (PI-RADS) ≥ 3, along with systematic biopsy. When PI-RADS lesions were p < 0.001). Decision curve analysis demonstrated a net benefit for both models compared with strategies of biopsy in all or no men. BCN-PM 2 showed greater net benefit than BCN-PM 1. At 95% sensitivity, BCN-PM 1 reduced MRI requests by 10.6%, while BCN-PM 2 avoided 19.4% of unnecessary biopsies. The sequential use of BCN-PM 1 and 2 resulted in a 10.6% reduction in MRI exams and a 23.1% reduction in biopsies, at the cost of missing 8.4% of csPCa cases. The performance of the biopsy improved from 53.7% to 64.0% (p < 0.001). Conclusions: BCN-PM1 and BCN-PM 2 were successfully validated in an Ibero-American population.